CHIP/STUB1 ubiquitin ligase functions as a negative regulator of ErbB2 by promoting its early post-biosynthesis degradation

Haitao Luan, Tameka A. Bailey, Robert J. Clubb, Bhopal C. Mohapatra, Aaqib M. Bhat, Sukanya Chakraborty, Namista Islam, Insha Mushtaq, Matthew D. Storck, Srikumar M. Raja, Vimla Band, Hamid Band

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Overexpression of the epidermal growth factor receptor (EGFR) family member ErbB2 (HER2) drives oncogenesis in up to 25% of invasive breast cancers. ErbB2 expression at the cell surface is required for oncogenesis but mechanisms that ensure the optimal cell surface display of overexpressed ErbB2 following its biosynthesis in the endoplasmic reticulum are poorly understood. ErbB2 is dependent on continuous association with HSP90 molecular chaperone for its stability and function as an oncogenic driver. Here, we use knockdown and overexpression studies to show that the HSP90/HSC70-interacting negative co-chaperone CHIP (C-terminus of HSC70-Interacting protein)/STUB1 (STIP1-homologous U-Box containing protein 1) targets the newly synthesized, HSP90/HSC70-associated, ErbB2 for ubiquitin/proteasome-dependent degradation in the endoplasmic reticulum and Golgi, thus identifying a novel mechanism that negatively regulates cell surface ErbB2 levels in breast cancer cells, consistent with frequent loss of CHIP expression previously reported in ErbB2-overexpressing breast cancers. ErbB2-overexpressing breast cancer cells with low CHIP expression exhibited higher endoplasmic reticulum stress inducibility. Accordingly, the endoplasmic reticulum stress-inducing anticancer drug Bortezomib combined with ErbB2-targeted humanized antibody Trastuzumab showed synergistic inhibition of ErbB2-overexpressing breast cancer cell proliferation. Our findings reveal new insights into mechanisms that control the surfaceexpression of overexpressed ErbB2 and suggest that reduced CHIP expression may specify ErbB2- overexpressing breast cancers suitable for combined treatment with Trastuzumab and ER stress inducing agents.

Original languageEnglish (US)
Article number3936
Issue number16
StatePublished - Aug 2 2021


  • Bortezomib
  • Breast cancer
  • Degradation
  • E3
  • Endoplasmic reticulum
  • ErbB2
  • Golgi
  • Pulse-chase
  • Trastuzumab
  • Ubiquitin
  • Ubiquitin ligase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'CHIP/STUB1 ubiquitin ligase functions as a negative regulator of ErbB2 by promoting its early post-biosynthesis degradation'. Together they form a unique fingerprint.

Cite this